The Natrelle 410 — Allergan's Most-Implanted Recalled Product
The Allergan Natrelle 410 Highly Cohesive Anatomically Shaped Silicone Breast Implant — commonly called the 410 or the 'gummy bear' implant due to its form-stable cohesive gel — was one of the most popular breast implants in the United States from its commercial introduction in the early 2000s through the July 2019 recall. The 410 uses Allergan's BIOCELL macro-textured surface, which the recall identified as the source of elevated BIA-ALCL risk. The Natrelle 410 was available in an extensive size and shape matrix (FM, FF, MM, MF, ML, LL, LM, LF, FX, MX, LX style codes) designed to provide natural anatomical shaping. All Natrelle 410 models in all sizes and style codes were included in the July 24, 2019 recall. Because the 410 was placed in a large volume of patients over nearly two decades, it is the most commonly identified implant model in MDL 2921 cases.
McGhan Textured Implants — Allergan's Legacy Brand
McGhan Medical Corporation was an implant manufacturer that was acquired by Inamed Corporation, which was subsequently acquired by Allergan in 2006. Textured breast implants manufactured under the McGhan brand name used the same BIOCELL surface technology that Allergan continued in its Natrelle product line. Women who received McGhan textured implants before the Allergan acquisition — or shortly after — may have BIOCELL implants under the McGhan brand name on their implant card or operative report. McGhan textured implants were included in the July 2019 recall. If your records show 'McGhan' as the implant manufacturer, consult an attorney — your implants may be covered by the same recall and eligible for the same MDL 2921 claims as Natrelle-branded BIOCELL products.
Other Recalled BIOCELL Models — Full Style List
Beyond the Natrelle 410, the July 2019 recall covered all BIOCELL textured product lines: Natrelle Silicone-Filled Textured Breast Implants (styles TRL, TRM, TRF, TRX, TSL, TSM, TSF, TSX, and full-projection variants TRL-FP, TRM-FP, TRF-FP, TRX-FP); Natrelle Saline-Filled Textured Breast Implants (styles 163, 168, 363, 468); Natrelle Inspira Textured Breast Implants; Natrelle 510 Dual-Gel Textured Breast Implants; BIOCELL Tissue Expanders (Natrelle 133 series — used in breast reconstruction after mastectomy); and all McGhan-branded textured implants. The recall did NOT cover smooth-surface Allergan implants, including smooth Inspira models and Natrelle Microcell products. If you are unsure whether your style number is in the recalled list, provide your implant style number to an attorney for confirmation.
Frequently Asked Questions
Related Pages
BIA-ALCL is not breast cancer — it is a T-cell lymphoma of the immune system that develops in the fluid or capsule surrounding Allergan BIOCELL textured implants. It is often curable when caught early, but advanced stages require chemotherapy and carry serious health consequences.
Learn moreBIA-ALCL staging — from Stage IA (confined to seroma fluid) through Stage IV (distant metastases) — is the single most important factor in determining the value of an Allergan breast implant lawsuit. Early-stage cases are curable; advanced stages require chemotherapy and carry worse prognosis and significantly higher compensation.
Learn moreThe July 24, 2019 Allergan BIOCELL recall was the largest breast implant recall in FDA history. It covered 33+ product lines after the FDA determined BIOCELL recipients faced a 6x elevated risk of BIA-ALCL lymphoma. French regulators had recalled the same product a year earlier in 2018.
Learn moreBreast implant illness (BII) is a constellation of systemic symptoms — fatigue, brain fog, joint pain, hair loss — reported by implant patients. Unlike BIA-ALCL, BII is not yet a formally recognized diagnosis, but BII plaintiffs with Allergan BIOCELL implants are included in MDL 2921 litigation.
Learn moreWomen who received Allergan BIOCELL textured implants or tissue expanders as part of post-mastectomy breast reconstruction after breast cancer are a distinct and especially sympathetic plaintiff class in MDL 2921. They fought breast cancer once — and Allergan's recalled product put them at risk of a second cancer.
Learn moreThe FDA does not recommend prophylactic removal of Allergan BIOCELL implants for asymptomatic patients. However, women who chose explantation after the recall may have legal claims for surgery costs. Women with BIA-ALCL symptoms require immediate medical evaluation — not observation.
Learn moreNo global Allergan BIOCELL settlement has been announced as of February 2026. The October 2026 bellwether trial will drive settlement negotiations. Based on comparable medical device MDLs, BIA-ALCL Stage IA cases may settle in the $50,000–$300,000 range; Stage IV cases may command $1,000,000–$3,000,000 or more.
Learn moreThe statute of limitations for Allergan BIOCELL claims is typically 2 to 3 years from discovery — meaning from BIA-ALCL diagnosis, not from implant placement or recall date. Discovery rule protections apply in most states. Consult an attorney immediately — deadlines are strict and MDL tolling is not automatic.
Learn moreYou may qualify if you received Allergan BIOCELL textured implants (for augmentation or reconstruction), were diagnosed with BIA-ALCL, or had your implants removed due to the recall. You do not need a cancer diagnosis to file. Implants already removed do not disqualify you.
Learn moreAllergan Breast Implant Lawsuit Lawsuit
Allergan (now owned by AbbVie) manufactured BIOCELL textured breast implants — including the widely used Natrelle 410 — that were found to cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious T-cell lymphoma of the immune system. The FDA determined that women with Allergan BIOCELL implants were approximately six times more likely to develop BIA-ALCL than women with implants from other manufacturers. On July 24, 2019, Allergan initiated a worldwide recall of all BIOCELL textured breast implants and tissue expanders. As of June 2023, the FDA had received 1,264 BIA-ALCL reports globally, with 1,079 — representing 85% of all cases — involving Allergan implants. Sixty-three deaths have been reported, with 37 linked to Allergan products. MDL 2921, In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, is pending before Judge Michael Martinotti in the District of New Jersey with approximately 1,400 cases. The first bellwether trial is scheduled for October 2026. Women who received Allergan BIOCELL textured implants, were diagnosed with BIA-ALCL, or underwent implant removal due to the recall may have viable legal claims.
View full case overview